Showing results (221-230 of 295) with videos related to

Sort By:
Pageof 30
Journal of Virological Methods|March 1, 1993
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolatesR W Shafer, M J Kozal, D A Katzenstein, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1982
Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combinationS L Sacks, G H Scullard, R B Pollard, et al.
Arthritis and Rheumatism|November 1, 1981
Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune diseaseE G Engleman, G Sonnenfeld, M Dauphinee, et al.
Hepatology (Baltimore, Md.)|January 1, 1982
Antiviral treatment of chronic hepatitis B virus infection: infectious virus cannot be detected in patient serum after permanent responses to treatmentG H Scullard, H B Greenberg, J L Smith, et al.
Antimicrobial Agents and Chemotherapy|January 1, 1986
Preliminary trial of recombinant fibroblast interferon in chronic hepatitis B virus infectionM Eisenberg, S Rosno, G Garcia, et al.
The New England Journal of Medicine|September 2, 1976
Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitisH B Greenberg, R B Pollard, L I Lutwick, et al.
JAMA|April 23, 1982
Vidarabine monophosphate and human leukocyte interferon in chronic hepatitis B infectionC I Smith, L W Kitchen, G H Scullard, et al.
Journal of Acquired Immune Deficiency Syndromes|August 1, 1994
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patientsM J Kozal, R W Shafer, M A Winters, et al.
Annals of Internal Medicine|August 15, 1994
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapyM J Kozal, K Kroodsma, M A Winters, et al.
Journal of Virology|October 24, 2000
Genotypic, phenotypic, and modeling studies of a deletion in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is associated with resistance to nucleoside reverse transcriptase inhibitorsM A Winters, K L Coolley, P Cheng, et al.
Pageof 30